The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Treatment outcomes in patients with discordant recurrence score and RSClin risk predictions.
 
Augustin Vannier
No Relationships to Disclose
 
Asim Dhungana
No Relationships to Disclose
 
Fangyuan Zhao
No Relationships to Disclose
 
Nan Chen
Employment - GlaxoSmithKline (I)
Consulting or Advisory Role - AstraZeneca; GE Healthcare; Gilead Sciences
 
Sarah Shubeck
No Relationships to Disclose
 
Olwen Mary Hahn
Employment - Solaris Health (I)
Leadership - Via Oncology
Stock and Other Ownership Interests - novavax; Teleflex Medical; Teleflex Medical
Honoraria - Cardinal Health (I)
Consulting or Advisory Role - HMP; Pfizer
Travel, Accommodations, Expenses - Cardinal Health (I)
 
Rita Nanda
Consulting or Advisory Role - AstraZeneca; BeyondSpring Pharmaceuticals; Cardinal Health; Fujifilm; GE Healthcare; Gilead Sciences; Infinity Pharmaceuticals; ITeos Therapeutics; Merck; OBI Pharma; OncoSec; Sanofi; Seagen
Research Funding - Arvinas (Inst); AstraZeneca (Inst); Celgene (Inst); Corcept Therapeutics (Inst); Genentech/Roche (Inst); Immunomedics (Inst); Merck (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); OncoSec (Inst); Pfizer (Inst); Relay Therapeutics (Inst); Seagen (Inst); Sun Pharma (Inst); Taiho Oncology (Inst)
Other Relationship - G1 Therapeutics
 
Nora T. Jaskowiak
No Relationships to Disclose
 
Gini F. Fleming
Honoraria - Physicans' Education Resource
Research Funding - Abbvie (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Celldex (Inst); Compugen (Inst); Compugen (Inst); Corcept Therapeutics (Inst); CytomX Therapeutics (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Iovance Biotherapeutics (Inst); K-Group Beta (Inst); Merck (Inst); Molecular Templates (Inst); P{fizer (Inst); Pfizer (Inst); Plexxikon (Inst); Roche (Inst); Sermonix Pharmaceuticals (Inst); Syros Pharmaceuticals (Inst)
Other Relationship - AstraZeneca (Inst); Caris Life Sciences (Inst); DSI (Inst); Eisai (Inst); Merck (Inst)
(OPTIONAL) Uncompensated Relationships - Abbvie
 
Olufunmilayo I. Olopade
Employment - CancerIQ (I)
Leadership - CancerIQ
Stock and Other Ownership Interests - 54gene; CancerIQ; HealthWell Solutions; Tempus
Consulting or Advisory Role - Tempus
Research Funding - Color Genomics (Inst); Roche/Genentech (Inst)
(OPTIONAL) Uncompensated Relationships - ACS; Susan G. Komen for the Cure
 
Alexander T. Pearson
Stock and Other Ownership Interests - Inovalon (I); Privo Technologies
Consulting or Advisory Role - Abbvie; Ayala Pharmaceuticals; Elevar Therapeutics; Prelude Therapeutics
Research Funding - Abbvie (Inst); Kura Oncology (Inst)
 
Dezheng Huo
No Relationships to Disclose
 
Frederick Matthew Howard
No Relationships to Disclose